UBS Remains Bullish Following Baxalta's (BXLT) Solid 4Q Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to UBS Remains Bullish Following Baxalta's (BXLT) Solid 4Q Results

Baxalta Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key Milestones

February 16, 2016 6:40 AM EST

Results reflect successful transition to a standalone company with compelling commercial, regulatory, clinical, operational and financial execution Broad and differentiated portfolio of leading hematology and immunology therapies driving sustainable growth and value Differentiated oncology portfolio augmented by pipeline progress and new, strategic immuno-oncology collaboration Significant advances toward delivering 20 new product launches by 2020 with key milestone achievements and FDA approvals of ADYNOVATE and VONVENDI

BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader... More